Guy Krippner
Directeur/Membre du Conseil chez Cardiora Pty Ltd.
Profil
Dr. Guy Krippner obtained his PhD from the University of Adelaide and completed post-doctoral research fellowships at both Oxford University and the University of Sydney.
Dr. Guy Krippner has had 16 years of experience in synthetic organic chemistry including 12 years as a senior Medicinal Chemist.
Previously, Dr. Guy Krippner was Head of Chemistry at Starpharma where he led a team of skilled synthetic and analytical chemists who collaborated with both commercial and academic partners to develop dendrimer based drug candidates for a variety of biological targets.
He has co-authored over 18 publications and is a co-inventor of 10 filed patents.
Postes actifs de Guy Krippner
| Sociétés | Poste | Début |
|---|---|---|
Cardiora Pty Ltd.
 Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
Anciens postes connus de Guy Krippner
| Sociétés | Poste | Fin |
|---|---|---|
Verva Pharmaceuticals Ltd.
 Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Corporate Officer/Principal | - |
Formation de Guy Krippner
| University of Adelaide | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Verva Pharmaceuticals Ltd.
Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Health Technology |
Cardiora Pty Ltd.
Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Miscellaneous |